Sagimet's stock ris­es af­ter Chi­na part­ner re­ports pos­i­tive Phase 3 da­ta in ac­ne

Sagimet Bio­sciences’ FASN in­hibitor deni­fan­stat suc­ceed­ed in a Chi­na-based Phase 3 tri­al in mod­er­ate-to-se­vere ac­ne that was run by its lo­cal part­ner As­cle­tis.

While that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER